Covington Represented uniQure in Sale of Gene Therapy Manufacturing Facility to Genezen

Covington Represented uniQure in Sale of Gene Therapy Manufacturing Facility to Genezen

July 23, 2024

WASHINGTON-Covington represented uniQure, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, in the sale of its Lexington, Massachusetts manufacturing facility to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus (AAV) technologies.

Genezen acquired uniQure's commercial-scale gene-therapy manufacturing facility for total consideration of $25 million, comprised of $12.5 million of newly issued Series C Preferred Stock and a $12.5 million convertible note. As a result of the transaction, uniQure becomes a meaningful shareholder of Genezen. In addition, Matt Kapusta, chief executive officer of uniQure, has joined Genezen's Board of Directors.